CoChat

Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)—study protocol for a randomized controlled trial

Open access
Wirth, Miranka, Schwarz, Claudia, Benson, Gloria, Horn, Nora, Buchert, Ralph, Lange, Catharina, Köbe, Theresa, Hetzer, Stefan, Maglione, Marta, Michael, Eva, Märschenz, Stefanie, Mai, Knut, Kopp, Ute, Schmitz, Dietmar, Grittner, Ulrike, Sigrist, Stephan J., Stekovic, Slaven, Madeo, Frank, Flöel, Agnes · 2019 · Alzheimer's Research & Therapy
Cited by 102

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Abstract

Background: Given the global increase in the aging population and age-related diseases, the promotion of healthy aging is one of the most crucial public health issues. This trial aims to contribute to the establishment of effective approaches to promote cognitive and brain health in older individuals with subjective cognitive decline (SCD). Presence of SCD is known to increase the risk of objective cognitive decline and progression to dementia due to Alzheimer’s disease. Therefore, it is our primary goal to determine whether spermidine supplementation has a positive impact on memory performance in this at-risk group, as compared with placebo. The secondary goal is to examine the effects of spermidine intake on other neuropsychological, behavioral, and physiological parameters. Methods: The SmartAge trial is a monocentric, randomized, double-blind, placebo-controlled phase IIb trial. The study will investigate 12 months of intervention with spermidine-based nutritional supplementation (target intervention) compared with 12 months of placebo intake (control intervention). We plan to recruit 100 cognitively normal older individuals with SCD from memory clinics, neurologists and general practitioners in private practice, and the general population. Participants will be allocated to one of the two study arms using blockwise randomization stratified by age and sex with a 1:1 allocation ratio. The primary outcome is the change in memory performance between baseline and post-intervention visits (12 months after baseline). Secondary outcomes include the change in memory performance from baseline to follow-up assessment (18 months after baseline), as well as changes in neurocognitive, behavioral, and physiological parameters (including blood and neuroimaging biomarkers), assessed at baseline and post-intervention. Discussion: The SmartAge trial aims to provide evidence of the impact of spermidine supplementation on memory performance in older individuals with SCD. In addition, we will identify possible neurophysiological mechanisms of action underlying the anticipated cognitive benefits. Overall, this trial will contribute to the establishment of nutrition intervention in the prevention of Alzheimer’s disease. Trial registration: ClinicalTrials.gov,NCT03094546. Registered 29 March 2017—retrospectively registered. Protocol version: Based on EA1/250/16 version 1.5

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-019-0484-1

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 102

Metadata

Authors
Wirth, M., Schwarz, C., Benson, G., Horn, N., Buchert, R., Lange, C., Köbe, T., Hetzer, S., Maglione, M., Michael, E., Märschenz, S., Mai, K., Kopp, U., Schmitz, D., Grittner, U., Sigrist, S. J., Stekovic, S., Madeo, F., & Flöel, A.
Venue
Alzheimer's Research & Therapy
Published
2019-05-01
Volume
11
Issue
1
Pages
36-36
ISSN
1758-9193 (ISSN-L)
OpenAlex
W2943109906
Cited by
102
References
26
FWCI
11.07
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)—study protocol for a randomized controlled trial. https://app.cochat.ai/papers/10.1186/s13195-019-0484-1
The paper
Wirth, M., Schwarz, C., Benson, G., Horn, N., Buchert, R., Lange, C., Köbe, T., Hetzer, S., Maglione, M., Michael, E., Märschenz, S., Mai, K., Kopp, U., Schmitz, D., Grittner, U., Sigrist, S. J., Stekovic, S., Madeo, F., & Flöel, A. (2019). Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline (SmartAge)—study protocol for a randomized controlled trial. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-019-0484-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.